Sheldon William Tobe

Sheldon William Tobe

Auto-generated profile, based on publicly available information

Sheldon William Tobe

Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Canada; Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada; Northern Ontario School of Medicine, Sudbury, Canada

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2011 in Circulation
Verified
Journal Article
Closed access
STSheldon W. Tobe
Sheldon W. Tobe
CCCatherine M. Clase
Catherine M. Clase
PGPeggy Gao
Peggy Gao
MMMatthew McQueen
Matthew McQueen
AGAnja Grosshennig
Anja Grosshennig
JMJohannes F.E. Mann
Johannes F.E. Mann
Background—: In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), dual therapy did not reduce cardiovascular or renal outcomes compared with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers alone. Previous controlled trials with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have demonstrated greater cardiovascular and renal benefit in people with renal risk. We hypothesized that dual therapy would be more effective than monotherapy in patients with low glomerular filtration rate and elevated albuminuria. Methods and Results—: Post hoc analysis was performed of renal subgroups of dual therapy versus monotherapy for the ONTARGET study and angiotensin receptor blocker versus placebo for the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND). The studies featured hazard ratios by subgroups and Cox regression models with factors for treatment, subgroup, and interactions. The main cardiovascular outcome was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure, and the main renal outcome was the composite of chronic dialysis or doubling of creatinine. In ONTARGET, there was no cardiovascular or renal benefit from dual over monotherapy in any subgroup, even with low glomerular filtration rate and/or elevated albuminuria. In TRANSCEND, in the comparison of angiotensin receptor blocker with placebo, there was a significant interaction for the main renal outcome ( P =0.01) in the direction of harm for patients with normoalbuminuria (0.37 versus 0.16 events per 100 patient-years; hazard ratio, 2.35; confidence interval, 1.33 to 4.15) but a trend to benefit with microalbuminuria (0.52 versus 0.89 events per 100 patient-years; hazard ratio, 0.60; confidence interval, 0.25 to 1.46) and macroalbuminuria (1.57 versus 2.60 events per 100 patient-years; hazard ratio, 0.71; confidence interval, 0.21 to 2.44). Conclusions—: This post hoc analysis does not support dual therapy over monotherapy in high–vascular risk patients with low glomerular filtration rate or albuminuria. This observation is a post hoc comparison and should be interpreted appropriately. Clinical Trial Registration—: URL: http://clinicaltrials.gov Identifier: NCT00153101.

14 September 2013 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
KBKimberly Blom
Kimberly Blom
BBBrian Baker
Brian Baker
MHMaxine How
Maxine How
MDMonica Dai
Monica Dai
JIJane Irvine
Jane Irvine
STSheldon W. Tobe
Sheldon W. Tobe
The HARMONY study was a randomized, controlled trial examining the efficacy of an 8-week mindfulness-based stress reduction (MBSR) program for blood pressure (BP) lowering among unmedicated stage 1 hypertensive participants. Participants diagnosed with stage 1 hypertension based on ambulatory BP were randomized to either immediate treatment of MBSR for 8 weeks or wait-list control. Primary outcome analysis evaluated whether change in awake and 24-hour ambulatory BP from baseline to week 12 was significantly different between the 2 groups. A within-group before and after MBSR analysis was also performed. The study enrolled 101 adults (38% male) with baseline average 24-hour ambulatory BP of 135±7.9/82±5.8mm Hg and daytime ambulatory BP of 140±7.7/87±6.3 mmHg. At week 12, the change from baseline in 24-hour ambulatory BP was 0.4±6.7/0.0±4.9mm Hg for the immediate intervention and 0.4±7.8/−0.4±4.6mm Hg for the wait-list control. There were no significant differences between intervention and wait-list control for all ambulatory BP parameters. The secondary within-group analysis found a small reduction in BP after MBSR compared with baseline, a finding limited to female subjects in a sex analysis. MBSR did not lower ambulatory BP by a statistically or clinically significant amount in untreated, stage 1 hypertensive patients when compared with a wait-list control group. It leaves untested whether MBSR might be useful for lowering BP by improving adherence in treated hypertensive participants. NCT00825526.

22 January 2016 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
MMMarion A Maar
Marion A Maar
KYKaren Yeates
Karen Yeates
ZTZsolt Toth
Zsolt Toth
MBMarcia Barron
Marcia Barron
LBLisa Boesch
Lisa Boesch
STSheldon W. Tobe
Sheldon W. Tobe
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

MNMark Niebylski
Mark Niebylski
TLTammy Lu
Tammy Lu
NCNorm Campbell
Norm Campbell
JAJoanne Arcand
Joanne Arcand
ASAlyssa Schermel
Alyssa Schermel
PLPeter P. Liu
Peter P. Liu
Unhealthy eating is the leading risk for death and disability globally. As a result, the World Health Organization (WHO) has called for population health interventions. One of the proposed interventions is to ensure healthy foods are available by implementing healthy food procurement policies. The objective of this systematic review was to evaluate the evidence base assessing the impact of such policies. A comprehensive review was conducted by searching PubMed and Medline for policies that had been implemented and evaluated the impact of food purchases, food consumption, and behaviors towards healthy foods. Thirty-four studies were identified and found to be effective at increasing the availability and purchases of healthy food and decreasing purchases of unhealthy food. Most policies also had other components such as education, price reductions, and health interventions. The multiple gaps in research identified by this review suggest that additional research and ongoing evaluation of food procurement programs is required. Implementation of healthy food procurement policies in schools, worksites, hospitals, care homes, correctional facilities, government institutions, and remote communities increase markers of healthy eating. Prior or simultaneous implementation of ancillary education about healthy eating, and rationale for the policy may be critical success factors and additional research is needed.

25 April 2006 in Canadian Medical Association Journal
Verified
Journal Article
Open access
PDF file
STSheldon W. Tobe
Sheldon W. Tobe
GPGeorge Pylypchuk
George Pylypchuk
JWJoan Wentworth
Joan Wentworth
AKAlexander Kiss
Alexander Kiss
JSJohn Paul Szalai
John Paul Szalai
JHJacqueline Hoppe
Jacqueline Hoppe
Background: First Nations people with diabetes mellitus and hypertension are at greater risk of renal and cardiovascular complications than are non-native patients because of barriers to health care services. We conducted this randomized controlled trial to assess whether a community-based treatment strategy implemented by home care nurses would be effective in controlling hypertension in First Nations people with existing hypertension and type 2 diabetes. Methods: We compared 2 community-based strategies for controlling hypertension in First Nations people with existing hypertension and diabetes. In the intervention group, a home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy. In the control group, treatment decisions were made by each subject9s primary care physician. The primary outcome measure was the difference between the 2 groups in the change in systolic blood pressure after 12 months. Secondary outcome measures were the change in diastolic blood pressure over time, the change in urine albumin status and the incidence of adverse events. Results: Both groups experienced a significant reduction in systolic blood pressure by the final visit (by 24.0 [standard deviation (SD) 13.5] mm Hg in the intervention group and by 17.0 [SD 18.6] mm Hg in the control group); p < 0.001 in each case). However, the difference between the 2 groups in this change was not significant. Patients in the intervention group had a larger decrease in diastolic blood pressure over time than did those in the control group (by 11.6 [SD 10.6] mm Hg v. 6.8 [SD 11.1] mm Hg respectively; p = 0.05). The groups did not differ significantly in terms of changes in urine albumin excretion or incidence of adverse events. Interpretation: High rates of blood pressure control in the community were achieved in both groups in the DREAM 3 study. The addition of a home care nurse to implement a treatment strategy for blood pressure control was more effective in lowering diastolic than systolic blood pressure compared with home care visits for blood pressure monitoring alone and follow-up treatment by a family physician.

1 February 2017 in Cardiology Clinics
Verified
Journal Article
Open access
AVAsha Vedanthan
Asha Vedanthan
ABAntonio Bernabe-Ortiz
Antonio Bernabe-Ortiz
OHOmarys I. Herasme
Omarys I. Herasme
RJRohina Joshi
Rohina Joshi
PLPatricio López-Jaramillo
Patricio López-Jaramillo
VFValentin Fuster
Valentin Fuster
Elevated blood pressure, a major risk factor for ischemic heart disease, heart failure, and stroke, is the leading global risk for mortality. Treatment and control rates are very low in low- and middle-income countries. There is an urgent need to address this problem. The Global Alliance for Chronic Diseases sponsored research projects focus on controlling hypertension, including community engagement, salt reduction, salt substitution, task redistribution, mHealth, and fixed-dose combination therapies. This paper reviews the rationale for each approach and summarizes the experience of some of the research teams. The studies demonstrate innovative and practical methods for improving hypertension control.